N. Haas

发表

Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.

Ian A Blair, Michael D Feldman, Kyoung-Jae Won, 2014, Cell metabolism.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

David C. Smith, E. Small, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas

J. Lewis, Xingmei Wang, D. Vaughn, 2014, Diabetes Care.

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

S. Litwin, G. Hudes, R. Greenberg, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician.

R. Uzzo, G. Hudes, P. Cairns, 2003, The Urologic clinics of North America.

Melanoma. Clinical practice guidelines in oncology.

A. Halpern, M. Ross, M. Martini, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma

P. Ott, M. Millward, A. Pavlick, 2010, PloS one.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

T. Choueiri, N. Agarwal, M. Harrison, 2019, The Lancet. Oncology.

Phase II trial of vorinostat in advanced melanoma

A. Oza, S. Litwin, S. Hotte, 2014, Investigational New Drugs.

Vinblastine and estramustine phosphate in metastatic renal cell carcinoma

S. Litwin, T. Halbherr, G. Hudes, 2003, Cancer.

Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.

T. Powles, T. Choueiri, C. Sternberg, 2018, European urology.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

I. Thompson, C. Tangen, E. Crawford, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1 Title: Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma

Kim, Ravi, P. Gimotty, 2019 .

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

J. Manola, K. Flaherty, M. Atkins, 2015, Clinical Cancer Research.

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

E. Lam, L. Fong, A. Mega, 2022, The oncologist.

Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines

M. Ross, J. Kirkwood, C. Slingluff, 2010, Journal of immunotherapy.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

J. Burke, T. Powles, T. Choueiri, 2021, The New England journal of medicine.

Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.

G. Hudes, L. Miller, L. Cisar, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide

Eun Jeong Min, Qi Long, K. Wellen, 2020, Prostate Cancer and Prostatic Diseases.

MacrophageMigration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell

Steven W. Johnson, P. O'dwyer, M. Selvakumaran, 2005 .

Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.

J. Manola, K. Flaherty, M. Atkins, 2015 .

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

M. Ross, J. Kirkwood, C. Slingluff, 2009, Clinical Cancer Research.

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

D. Smith, E. Small, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive Cellular Therapy for Solid Tumors.

V. Narayan, M. O'Hara, N. Haas, 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer

T. Dorff, C. June, V. Narayan, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805

J. Manola, D. Cella, R. DiPaola, 2018, Quality of Life Research.

Kidney Cancer, Version 3.2022

S. Hancock, R. Motzer, E. Jonasch, 2021 .

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives

V. Narayan, N. Haas, 2016, International journal of nephrology and renovascular disease.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

T. Powles, T. Choueiri, S. Park, 2021 .

Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma

R. Motzer, P. Russo, C. Sternberg, 2018, Clinical Cancer Research.

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).

P. Catalano, Catherine J. Wu, S. Signoretti, 2020 .

Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800)

J. Manola, G. Wilding, R. Dreicer, 2007, Cancer.

Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC).

G. Adluru, K. Flaherty, A. Troxel, 2009, Journal of Clinical Oncology.

Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.

C. Langer, N. Haas, N. Haas, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.

Chad A. LaGrange, Geoffrey E. Wile, S. Hancock, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

F. Saad, C. Olsson, D. Rathkopf, 2015, The Prostate.

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward

J. Manola, S. Signoretti, B. Shuch, 2017, Kidney cancer.

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

G. Hudes, B. Roth, James F. Babb, 2001, Urology.

Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies.

N. Haas, Pearl Subramanian, 2018, Urologic oncology.

Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer—20 Years Later, and the Answer Is Still Yes

N. Haas, S. Takvorian, Samuel U. Takvorian, 2021, JAMA network open.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

S. Signoretti, B. Leibovich, T. Choueiri, 2019, Future oncology.

BLIMP1 and NR4A3 Transcription Factors Reciprocally Regulate Antitumor CAR T-cell Stemness and Exhaustion

S. Berger, V. Narayan, D. Siegel, 2022, Science Translational Medicine.

Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors.

M. Einarson, M. von Mehren, G. Hudes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

R. Figlin, K. Foon, J. Gollob, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

P. Ott, Juanita Lopez, S. Piha-Paul, 2016 .

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

R. Sebro, C. June, J. Melenhorst, 2019 .

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

E. Plimack, S. Litwin, M. von Mehren, 2014, The oncologist.

Emphysematous Pyelonephritis Caused by Pasteurella multocida March

Y. Wong, B. Suh, R. Parsons, 2017 .

Emphysematous Pyelonephritis Caused by Pasteurella multocida

Mbbs, Y. Wong, B. Suh, 2009 .

Radiation and immunotherapy: a synergistic combination.

C. June, N. Vapiwala, N. Haas, 2013, The Journal of clinical investigation.

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

F. Bushman, R. Sebro, B. Levine, 2022, Nature Medicine.

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.

S. Hancock, R. Motzer, E. Jonasch, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II Pilot Study of Combined Chemohormonal Therapy With Doxorubicin and Estramustine in Metastatic Prostate Cancer: Eastern Cooperative Oncology Group Study PH882

J. Manola, G. Hudes, D. Citrin, 2000, American journal of clinical oncology.

Findings of intramediastinal gossypiboma with F-18 FDG PET in a melanoma patient.

R. Parsons, J. Yu, M. Doss, 2008, Clinical nuclear medicine.

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

S. Signoretti, T. Choueiri, N. Agarwal, 2017, European urology.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

J. Manola, K. Flaherty, T. Choueiri, 2016, The Lancet.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Chad A. LaGrange, Geoffrey E. Wile, R. Advani, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

D. Potvin, K. Papadopoulos, D. Rasco, 2022, Targeted Oncology.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

P. Ott, Juanita Lopez, S. Piha-Paul, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo

J. Testa, P. O'dwyer, K. Yao, 2005, British Journal of Cancer.

Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.

W. Curran, S. Litwin, C. Langer, 1996, The cancer journal from Scientific American.

Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone‐refractory prostate cancer

R. Uzzo, P. Crispen, N. Haas, 2008, Cancer.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma

J. Manola, K. Flaherty, M. Atkins, 2019, Clinical Cancer Research.

Surveillance for Renal Cell Cancer Recurrence: Which Patients Should Undergo Imaging, How Often, and When?

N. Haas, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hereditary kidney cancer syndromes.

K. Nathanson, N. Haas, 2014, Advances in chronic kidney disease.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Keith T Flaherty, Paul S Meltzer, Maria J Merino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

J. Manola, K. Flaherty, T. Choueiri, 2017, JAMA oncology.

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

J. Manola, E. Messing, K. Flaherty, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors

P. Gimotty, J. Sosman, H. Tawbi, 2017, Clinical Cancer Research.

Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).

R. Motzer, P. Russo, R. Motzer, 2017 .

Adjuvant therapy for renal cell carcinoma: past, present, and future.

S. Pal, N. Haas, 2014, The oncologist.

A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500.

I. Thompson, C. Tangen, B. Shuch, 2017 .

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

P. Catalano, Catherine J. Wu, S. Signoretti, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapies for kidney cancer in urologic practice.

R. Uzzo, N. Haas, 2007, Urologic oncology.

Tyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney Cancer

R. Uzzo, N. Haas, 2007, Current treatment options in oncology.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

R. Figlin, R. Motzer, M. Voss, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Macrophage Migration Inhibitory Factor Is a Determinant of Hypoxia-Induced Apoptosis in Colon Cancer Cell Lines

Steven W. Johnson, P. O'dwyer, K. Yao, 2005, Clinical Cancer Research.

Adjuvant therapy for renal cell carcinoma

R. Uzzo, N. Haas, 2008, Current oncology reports.

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

I. Thompson, C. Tangen, E. Crawford, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial

J. Manola, D. Cella, R. DiPaola, 2018, Supportive Care in Cancer.

Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

T. Guzzo, A. Wein, W. Hwang, 2012, International journal of radiation oncology, biology, physics.

Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer.

T. Guzzo, C. Pollack, N. Vapiwala, 2010, International journal of radiation oncology, biology, physics.

Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment.

T. Guzzo, K. Armstrong, N. Vapiwala, 2011, Urology.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

R. Figlin, R. Motzer, M. Voss, 2017 .

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

D. Heitjan, A. Nixon, S. Eliasof, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

G. Shapiro, R. Prinjha, I. Braña, 2019, JNCI cancer spectrum.

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.

T. Choueiri, E. Plimack, J. Coleman, 2019, JAMA oncology.

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma

P. Gimotty, Sabah Kadri, L. Appleman, 2019, Clinical Cancer Research.

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours

E. Wherry, A. DeMichele, A. Minn, 2018, British Journal of Cancer.

Adjuvant therapy for high-risk renal cell carcinoma patients

R. Uzzo, D. Kunkle, N. Haas, 2007, Current urology reports.

Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder Retroperitoneal Lymphadenectomy for High Risk , Nonmetastatic Renal Cell Carcinoma : An Analysis of the ASSURE ( ECOG-ACRIN 2805 ) Adjuvant Trial

J. Manola, E. Messing, C. Wood, 2017 .

Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma.

R. Uzzo, C. Fung, N. Haas, 2011, Hematology/oncology clinics of North America.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

S. Hancock, R. Motzer, E. Jonasch, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.

T. Powles, T. Choueiri, S. Park, 2022, Journal of Clinical Oncology.

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population

J. Manola, R. DiPaola, S. Buti, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

David C. Smith, E. Basch, H. Scher, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

David C. Smith, E. Basch, A. Bennett, 2015, European urology.

Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.

M. Ross, C. Slingluff, W. Grosh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.

M. Sundaram, Yan Song, J. Signorovitch, 2022, Journal of managed care & specialty pharmacy.

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

E. V. Van Allen, S. Signoretti, T. Choueiri, 2019 .

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

S. Signoretti, B. Leibovich, T. Choueiri, 2019, Journal of Clinical Oncology.

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

R. Ozols, P. O'dwyer, G. Hudes, 1994, Cancer research.

Clinical, pharmacokinetic and biological studies of topotecan

P. O'dwyer, T. Halbherr, K. Yao, 2004, Cancer Chemotherapy and Pharmacology.

Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.

Hao Wang, G. Hudes, A. Murgo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

Xin Victoria Wang, Keith T Flaherty, J. Manola, 2017, Clinical Cancer Research.

Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma

R. Hubbard, N. Agarwal, R. Townsend, 2018, Circulation. Heart failure.

Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial

R. DiPaola, R. Uzzo, V. Narayan, 2019, The Journal of urology.

Kidney cancer, version 1.2021: Featured updates to the nccn guidelines

S. Hancock, R. Motzer, E. Jonasch, 2020 .

Cell Metabolism Metabolic Control of Tumor Histone Acetylation in methylation changes in cancer cells

B. Garcia, L. Chodosh, T. Rebbeck, 2022 .

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours

E. Wherry, A. DeMichele, A. Minn, 2018, British Journal of Cancer.

Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.

R. Srinivasan, M. Voss, A. DeMichele, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy.

C. Deville, N. Vapiwala, R. Mick, 2017, International journal of radiation oncology, biology, physics.

Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.

J. Manola, E. Messing, K. Flaherty, 2020, The Journal of urology.

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

N. Agarwal, B. Costello, R. DiPaola, 2019, Journal of Clinical Oncology.

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

R. Sebro, C. June, J. Melenhorst, 2019, Journal of Clinical Oncology.

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

P. Subedi, Pengxiang Li, J. Doshi, 2015, Cancer medicine.

Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

K. Flaherty, R. DiPaola, R. Uzzo, 2021, Clinical Cancer Research.

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States.

N. Haas, R. Bhattacharya, A. Bensimon, 2023, Clinical genitourinary cancer.

LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

S. Signoretti, B. Leibovich, M. Michaelson, 2022, Annals of Oncology.

Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy.

M. Sundaram, Yan Song, J. Signorovitch, 2021 .

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.

R. Motzer, P. Russo, T. Choueiri, 2021, European urology.

CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

R. Srinivasan, M. Voss, G. Shapiro, 2019, Journal of Clinical Oncology.

Phase II study of vorinostat in patients with advanced melanoma.

A. Oza, S. Litwin, D. Hogg, 2010 .

A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM).

M. Millward, A. Pavlick, F. Muggia, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features.

J. Manola, G. Wilding, E. Heath, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Therapy vs Surveillance in Patients with Resected Early-Stage Intermediate to High-Risk Renal Cell Carcinoma

N. Haas, C. Major, Carlos I. Rodriguez, 2023, Kidney Cancer.

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.

J. Manola, E. Messing, K. Flaherty, 2021, European urology.

Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?

R. Uzzo, N. Haas, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II trial of weekly infusional 5-fluorouracil in combination with lowdose leucovorin in patients with advanced colorectal cancer

R. Ozols, L. Weiner, P. O'dwyer, 2004, Investigational new drugs.

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

J. Manola, E. Heath, G. Wilding, 2012, Medical Oncology.

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.

S. Signoretti, A. Hakimi, E. Jonasch, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma

N. Agarwal, I. Puzanov, M. Putt, 2017, Clinical Cancer Research.

Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).

David C. Smith, H. Scher, J. Bono, 2012 .

Disease‐free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results‐Medicare datac

Yan Song, J. Signorovitch, N. Haas, 2023, International journal of urology : official journal of the Japanese Urological Association.

Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

T. Choueiri, S. Park, P. Tomczak, 2023, Journal of Clinical Oncology.

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

P. Catalano, M. Atkins, E. Plimack, 2023, Journal of Clinical Oncology.

ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial.

A. Tolcher, A. Pantuck, L. Denis, 2016 .

PD10-04 LYMPHADENECTOMY AT THE TIME OF SURGERY FOR HIGH RISK LOCALIZED RCC: RESULTS FROM THE ASSURE ADJUVANT TRIAL (ECOG 2805)

J. Manola, C. Wood, R. DiPaola, 2014 .

A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).

S. Signoretti, T. Choueiri, M. Michaelson, 2017 .

Microvessel density as a prognostic marker in high-risk renal cell carcinoma.

Xin Victoria Wang, Robert S. DiPaola, J. Manola, 2017 .

Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction.

F. Bushman, S. Berger, D. Porter, 2023, Cancer discovery.

Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC).

J. Manola, K. Flaherty, M. Atkins, 2012 .

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

S. Signoretti, B. Leibovich, T. Choueiri, 2019, Journal of Clinical Oncology.

Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?

R. Flippot, L. Albiges, N. Haas, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124.

I. Thompson, C. Tangen, E. Crawford, 2017 .

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

R. DiPaola, D. Gerber, C. Murphy, 2021, Cancer medicine.

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.

J. Manola, E. Plimack, R. DiPaola, 2023, Clinical genitourinary cancer.

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.

Chad A. LaGrange, Geoffrey E. Wile, S. Hancock, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805.

D. Cella, R. DiPaola, B. Ky, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment

T. Ho, M. Atkins, Siraj M. Ali, 2019, Annals of Oncology.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

David C. Smith, E. Small, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

David C. Smith, E. Basch, A. Bennett, 2015, European urology.

Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805

J. Manola, D. Cella, R. DiPaola, 2018, Quality of Life Research.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients.

V. Narayan, R. Pili, T. Logan, 2020 .

Phase I trial of 5-fluorouracil by 24-hour infusion weekly

R. Ozols, P. O'dwyer, G. Hudes, 1993, Investigational New Drugs.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

J. Manola, K. Flaherty, R. DiPaola, 2017, Clinical Cancer Research.

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial

J. Manola, D. Cella, R. DiPaola, 2018, Supportive Care in Cancer.

Adjuvant therapy for high-risk renal cell carcinoma patients

R. Uzzo, D. Kunkle, N. Haas, 2007, Current urology reports.

Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial

L. Fong, M. Stein, R. Perini, 2015, Journal of Immunotherapy for Cancer.

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.

J. Manola, R. DiPaola, S. Buti, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel.

E. Lam, L. Fong, A. Mega, 2020 .

International Journal of Nephrology and Renovascular Disease Dovepress Axitinib in the Treatment of Renal Cell Carcinoma: Patient Selection and Perspectives

V. Narayan, N. Haas, 2022 .

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

P. Humphrey, C. Tangen, B. Shuch, 2021 .

Association between age and sex and mortality after adjuvant therapy for renal cancer

B. Gyawali, R. DiPaola, C. Epperson, 2019, Cancer.